About N-acetylglucosaminyl-phosphatidylinositol de-N-acetylase
N-acetylglucosaminyl-phosphatidylinositol de-N-acetylase (PIGL) is a protein
from Homo sapiens identified by UniProt accession
Q9Y2B2, 252 residues long.
MolForge cross-references it against 0 known binders and
65 disease associations.
Target properties
| Protein name | N-acetylglucosaminyl-phosphatidylinositol de-N-acetylase |
|---|
| UniProt accession | Q9Y2B2 |
|---|
| Gene | PIGL |
|---|
| Organism | Homo sapiens |
|---|
| Length | 252 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (65)
Diseases linked to this target (Open Targets).
- CHIME syndrome · score 0.79
- leukocyte count · score 0.45
- neutrophil count · score 0.44
- hyperphosphatasia-intellectual disability syndrome · score 0.44
- genetic disorder · score 0.41
- myeloid white cell count · score 0.39
- neutrophil percentage of leukocytes · score 0.38
- syndromic intellectual disability · score 0.37
- lymphocyte percentage of leukocytes · score 0.37
- monocyte percentage of leukocytes · score 0.34
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9Y2B2-F1 | alphafold | PREDICTED | 91.74 | — |
Amino-acid sequence (252 residues)
MEAMWLLCVA LAVLAWGFLW VWDSSERMKS REQGGRLGAE SRTLLVIAHP DDEAMFFAPT VLGLARLRHW VYLLCFSAGN YYNQGETRKK ELLQSCDVLG IPLSSVMIID NRDFPDDPGM QWDTEHVARV LLQHIEVNGI NLVVTFDAGG VSGHSNHIAL YAAVRALHSE GKLPKGCSVL TLQSVNVLRK YISLLDLPLS LLHTQDVLFV LNSKEVAQAK KAMSCHRSQL LWFRRLYIIF SRYMRINSLS FL
Explore N-acetylglucosaminyl-phosphatidylinositol de-N-acetylase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets